Zymeworks (ZYME) Gains from Investment Securities (2021 - 2026)
Zymeworks recorded quarterly Gains from Investment Securities of $245000.0 in Q1 2026, up 119.71% quarter-over-quarter from -$1.2 million in Q4 2025, and down 36.69% year-over-year from $387000.0 in Q1 2025.
Zymeworks' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $245000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 36.69% year-over-year to $245000.0; the TTM figure through Mar 2026 stood at -$998000.0 (down 145.86% YoY), while the FY2024 annual figure was $3.2 million, up 404.6% from the prior year.
- Gains from Investment Securities came in at $245000.0 for Q1 2026 at Zymeworks, up from -$1.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $3.0 million in Q4 2024 to a low of -$1.2 million in Q4 2025.
- A 5-year average of $129833.3 and a median of $11500.0 in 2022 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 381.66% in 2024 and fell as far as 23460.0% in 2024.
- Zymeworks' Gains from Investment Securities stood at -$322000.0 in 2022, then surged by 291.3% to $616000.0 in 2023, then soared by 381.66% to $3.0 million in 2024, then tumbled by 141.89% to -$1.2 million in 2025, then jumped by 119.71% to $245000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $245000.0, -$1.2 million, and $387000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 245,000.00 |
| Mar 31, 2026 | 245,000.00 |
| Dec 31, 2025 | -1.24 Mn |
| Dec 31, 2025 | -1.24 Mn |
| Mar 31, 2025 | 387,000.00 |
| Mar 31, 2025 | 387,000.00 |
| Dec 31, 2024 | 2.97 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Dec 31, 2023 | 616,000.00 |
| Dec 31, 2023 | 616,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | -322,000.00 |
| Dec 31, 2022 | -322,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Dec 31, 2021 | 5,000.00 |